PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Plasma fibrinogen level may be a possible marker for the clinical response and prognosis of patients with breast cancer receiving neoadjuvant chemotherapy.

Abstract Neoadjuvant chemotherapy has been established as standard treatments for advanced breast cancer among multidisciplinary therapies. A simple and instructive biomarker for the postoperative recurrence and metastasis is needed to evaluate the therapeutic effect. Plasma fibrinogen level has been shown to be associated with tumor progression and poor outcomes in breast cancer patients. This study aims to further evaluate the clinical and prognostic value of plasma fibrinogen level as a biomarker in breast cancer patients receiving neoadjuvant chemotherapy. In this study, data of 67 patients were retrospectively collected and analyzed to identify the relationship between the plasma fibrinogen level and the clinical progression and outcome of these patients. Patients with increased plasma fibrinogen level after neoadjuvant chemotherapy had significantly shorter disease-free survival and overall survival (p < 0.001 and p = 0.001, respectively). In a univariate survival analysis, molecular type (p = 0.0004/p = 0.005), clinical response (p = 0.008/p = 0.015), and changes in plasma fibrinogen level (p = 0.012/p = 0.007) were associated with disease-free survival and overall survival, and all of them, molecular type (p = 0.0003/p = 0.005), clinical response (p = 0.027/p = 0.021), and changes in plasma fibrinogen level (p = 0.035/p = 0.025), were associated with disease-free survival and overall survival in a multivariate survival analysis, respectively. The plasma fibrinogen level was found to be a possible biomarker for clinical response to chemotherapy and postoperative metastasis or death in advanced breast cancer patients who received neoadjuvant chemotherapy.
PMID
Related Publications

SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.

Tumor response and survival in patients with advanced non-small-cell lung cancer: the predictive value of chemotherapy-induced changes in fibrinogen.

Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.

Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.

Clinical significance of plasma fibrinogen level as a predictive marker for postoperative recurrence of esophageal squamous cell carcinoma in patients receiving neoadjuvant treatment.

Authors

Mayor MeshTerms
Keywords

Fibrinogen

breast cancer

neoadjuvant chemotherapy

prognosis

tumor marker

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28621233
OWN - NLM
STAT- MEDLINE
DA  - 20170616
DCOM- 20170705
LR  - 20170705
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 6
DP  - 2017 Jun
TI  - Plasma fibrinogen level may be a possible marker for the clinical response and
      prognosis of patients with breast cancer receiving neoadjuvant chemotherapy.
PG  - 1010428317700002
LID - 10.1177/1010428317700002 [doi]
AB  - Neoadjuvant chemotherapy has been established as standard treatments for advanced
      breast cancer among multidisciplinary therapies. A simple and instructive
      biomarker for the postoperative recurrence and metastasis is needed to evaluate
      the therapeutic effect. Plasma fibrinogen level has been shown to be associated
      with tumor progression and poor outcomes in breast cancer patients. This study
      aims to further evaluate the clinical and prognostic value of plasma fibrinogen
      level as a biomarker in breast cancer patients receiving neoadjuvant
      chemotherapy. In this study, data of 67 patients were retrospectively collected
      and analyzed to identify the relationship between the plasma fibrinogen level and
      the clinical progression and outcome of these patients. Patients with increased
      plasma fibrinogen level after neoadjuvant chemotherapy had significantly shorter 
      disease-free survival and overall survival (p &lt; 0.001 and p = 0.001,
      respectively). In a univariate survival analysis, molecular type (p = 0.0004/p = 
      0.005), clinical response (p = 0.008/p = 0.015), and changes in plasma fibrinogen
      level (p = 0.012/p = 0.007) were associated with disease-free survival and
      overall survival, and all of them, molecular type (p = 0.0003/p = 0.005),
      clinical response (p = 0.027/p = 0.021), and changes in plasma fibrinogen level
      (p = 0.035/p = 0.025), were associated with disease-free survival and overall
      survival in a multivariate survival analysis, respectively. The plasma fibrinogen
      level was found to be a possible biomarker for clinical response to chemotherapy 
      and postoperative metastasis or death in advanced breast cancer patients who
      received neoadjuvant chemotherapy.
FAU - Mei, Yu
AU  - Mei Y
AD  - 1 Department of Breast Surgery, Jinan Maternity and Child Care Hospital, Jinan,
      P.R. China.
AD  - 2 Department of Breast Surgery, Qilu Hospital of Shandong University, Jinan, P.R.
      China.
FAU - Liu, Haixia
AU  - Liu H
AD  - 3 Department of Pathology, Jinan Maternity and Child Care Hospital, Jinan, P.R.
      China.
FAU - Sun, Xiaorong
AU  - Sun X
AD  - 3 Department of Pathology, Jinan Maternity and Child Care Hospital, Jinan, P.R.
      China.
FAU - Li, Xiangyi
AU  - Li X
AD  - 4 School of Public Health, Shandong University, Jinan, P.R. China.
FAU - Zhao, Song
AU  - Zhao S
AD  - 2 Department of Breast Surgery, Qilu Hospital of Shandong University, Jinan, P.R.
      China.
FAU - Ma, Rong
AU  - Ma R
AD  - 2 Department of Breast Surgery, Qilu Hospital of Shandong University, Jinan, P.R.
      China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
RN  - 0 (Biomarkers, Tumor)
RN  - 9001-32-5 (Fibrinogen)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*blood
MH  - Breast Neoplasms/blood/*drug therapy/genetics/pathology
MH  - Disease-Free Survival
MH  - Female
MH  - Fibrinogen/*metabolism
MH  - Humans
MH  - Middle Aged
MH  - Neoadjuvant Therapy
MH  - Neoplasm Recurrence, Local/*blood/pathology
MH  - Prognosis
OTO - NOTNLM
OT  - Fibrinogen
OT  - breast cancer
OT  - neoadjuvant chemotherapy
OT  - prognosis
OT  - tumor marker
EDAT- 2017/06/18 06:00
MHDA- 2017/07/06 06:00
CRDT- 2017/06/17 06:00
AID - 10.1177/1010428317700002 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Jun;39(6):1010428317700002. doi: 10.1177/1010428317700002.